Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

• Vincent Meininger,

  Affiliation Département des Maladies du Système Nerveux, Assistance Publique – Hôpitaux de Paris, Centre de Référence Maladies Rares SLA, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre-et-Marie-Curie, Paris, France

  ⨯
• Pierre-François Pradat,

  Affiliations Département des Maladies du Système Nerveux, Assistance Publique – Hôpitaux de Paris, Centre de Référence Maladies Rares SLA, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre-et-Marie-Curie, Paris, France, Unité Mixte de Recherche-678, Institut National de la Santé et de la Recherche Médicale - Université Pierre-et-Marie-Curie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

  ⨯
• Andrea Corse,

  Affiliation Neuromuscular Pathology Lab, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

  ⨯
• Safa Al-Sarraj,

  Affiliation Department of Clinical Neuropathology, Kings College Hospital/Kings College London, London, United Kingdom

  ⨯
• Benjamin Rix Brooks,

  Affiliation Carolinas Neuromuscular/Amyotrophic Lateral Sclerosis-Muscular Dystrophy Association Center, Department of Neurology, Carolinas Medical Center and University of North Carolina School of Medicine-Charlotte Campus, Charlotte, North Carolina, United States of America

  ⨯
• James B. Caress,

  Affiliation Wake Forest School of Medicine, M Reynolds Tower, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America

  ⨯
• Merit Cudkowicz,

  Affiliation Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Stephen J. Kolb,

  Affiliation Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America

  ⨯
• Dale Lange,

  Affiliation Department of Neurology, Weill Cornell School of Medicine, New York, New York, United States of America

  ⨯
• P. Nigel Leigh,

  Affiliation Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, Falmer, Sussex, United Kingdom

  ⨯
• Thomas Meyer,

  Affiliation Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany

  ⨯
• Stefano Milleri,

  Affiliation Centro Ricerche Cliniche, University Hospital G.B. Rossi, Verona, Italy

  ⨯
• Karen E. Morrison,

  Affiliation School of Clinical and Experimental Medicine, University of Birmingham and Neurosciences Department, Queen Elizabeth Hospital, Birmingham, United Kingdom

  ⨯
• Richard W. Orrell,

  Affiliations Department of Clinical Neuroscience, Institute of Neurology, University College London, London, United Kingdom, Department of Neurology, Royal Free London NHS Foundation Trust, London, United Kingdom

  ⨯
• Gary Peters,

  Affiliation GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom

  ⨯
• Jeffrey D. Rothstein,

  Affiliation Brain Science Institute, Johns Hopkins University, Department of Neurology, Baltimore, Maryland, United States of America

  ⨯
• Jeremy Shefner,

  Affiliation Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, United States of America

  ⨯
• Arseniy Lavrov ,

  * E-mail: arseniy.j.lavrov@gsk.com

  Affiliation Neurosciences Therapy Area Unit, Medicines Discovery and Development, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom

  ⨯
• Nicola Williams,

  Affiliation Clinical Statistics, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

  ⨯
• Phil Overend,

  Affiliation Clinical Statistics, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

  ⨯
• Jeffrey Price,

  Affiliation Clinical Pharmacology, Science and Study Operations, BioPharm and Infectious Diseases, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

  ⨯
• Stewart Bates,

  Affiliation BioPharm Translational Medicine, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

  ⨯
• Jonathan Bullman,

  Affiliation Clinical Pharmacology Modelling & Simulation (Neurosciences), GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

  ⨯
• David Krull,

  Affiliation Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Alienor Berges,

  Affiliation Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom

  ⨯
• Bams Abila,

  Affiliation BioPharm Translational Medicine, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

  ⨯
• Guy Meno-Tetang,

  Affiliation Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom

  ⨯
•  [ ... ],
• Jens Wurthner

  Affiliation Oncology Translational Medicine, Novartis Basel, Switzerland

  ⨯
• [ view all ]
• [ view less ]